摘要
目的 分析卡瑞利珠单抗联合含铂双药方案一线治疗非小细胞肺癌(NSCLC)的临床疗效。方法 收集濮阳市安阳地区医院2020年1月至2022年12月行含铂双药方案治疗的82例驱动基因阴性晚期NSCLC患者临床资料,其中行卡瑞利珠单抗联合含铂双药一线治疗的有38例(观察组),仅行含铂双药一线治疗的有44例(对照组)。记录两组临床疗效[客观有效率(ORR)、疾病控制率(DCR)],比较两组治疗前及治疗4个周期后T淋巴细胞亚群(CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))变化,分析两组患者生存情况[包括无进展生存(PFS)及总生存(OS)],并评估治疗不良反应。结果 观察组ORR及DCR均显著高于对照组(P<0.05)。治疗4个周期后,两组外周血CD4^(+)及CD4^(+)/CD8^(+)均较治疗前升高(P<0.05),且观察组治疗后高于对照组(P<0.05);两组外周血CD8^(+)均较治疗前降低(P<0.05),且观察组治疗后低于对照组(P<0.05)。观察组1年PFS率及OS率分别为73.68%(28/38)、76.32%(29/38),对照组1年PFS率及OS率分别为45.45%(20/44)、52.27%(23/44),观察组1年PFS率及OS率明显高于对照组(P<0.05)。Kaplan-Meier法绘制生存曲线,Log Rank法检验显示,观察组PFS期及OS期明显高于对照组(P<0.05)。观察组反应性皮肤毛细血管增生症发生率高于对照组(P<0.05)。结论 卡瑞利珠单抗联合含铂双药方案一线治疗驱动基因阴性晚期NSCLC可改善患者免疫功能,较单纯化疗可提高ORR与DCR,并延长PFS期及OS期,可使晚期NSCLC更佳获益。
Objective To analyze the clinical efficacy of camrelizumab combined with platinum-containing dual-drug regimen first-line therapyon non-small cell lung cancer(NSCLC).Methods Clinical data of 82 patients withdriver gene-negativeadvanced NSCLC who received platinum-containing dual-drug regimen in the hospital from January 2020 to December 2022 were collected.Among the patients,38 cases were given camrelizumab combined with platinum-containingdual-drugfirst-line therapy(observation group),and 44 cases received platinum-containing dual-drug first-line therapy only(control group).The clinical efficacy[objective response rate(ORR),disease control rate(DCR)]in the two groups were recorded,and the changes in T lymphocyte subsets(CD4^(+),CD8^(+),CD4^(+)/CD8^(+))were compared between the two groups before treatment and after 4 cycles of treatment,and the survival status[progression-free survival(PFS),overall survival(OS)]in the two groups were analyzed,and the adverse re⁃actions of treatment were evaluated.Results The ORR and DCR in observation group were significantly higher than those in control group(P<0.05).After 4 cycles of treatment,the CD4^(+)and CD4^(+)/CD8^(+)in peripheral blood of both groups were enhanced compared with those before treatment(P<0.05),and the indicators in observation group after treatment were higher than those in control group(P<0.05).Peripheral blood CD8^(+)in both groups was reduced com⁃pared with that before treatment(P<0.05),and the CD8^(+)inobservation group was lower than that in control group af⁃ter treatment(P<0.05).The 1-year PFS rate and OS rate in observation group were 73.68%(28/38)and 76.32%(29/38)and those in control group were 45.45%(20/44)and 52.27%(23/44)respectively.The 1-year PFS rate and OS rate in observation group were significantly higher than those in control group(P<0.05).According to the survival curve plotted by Kaplan-Meier method,Log Rank test showed that the PFS and OS in observation group were sig⁃nificantly longer than those in control group(P<0.05).The incidence rate of reactive cutaneous capillary hyperplasia in observation group was higher than that in control group(P<0.05).Conclusion Camrelizumab combined with plati⁃num-containing dual-drug regimenfirst-line therapy can improve the immune function of patients with driver gene-negativeadvanced NSCLC,and can better increase the ORR and DCR and prolong the PFS and OS compared to chemo⁃therapy alone,and it can provide better benefits for advanced NSCLC.
作者
孙李凌
刘晓风
付亚如
SUN Li-ling;LIU Xiao-feng;FU Ya-ru(Department of Oncology,Anyang District Hospital of Puyang City,Anyang,Henan 455000,China)
出处
《医药论坛杂志》
2023年第20期44-49,共6页
Journal of Medical Forum
关键词
非小细胞肺癌
卡瑞利珠单抗
含铂双药
治疗效果
淋巴细胞
Non-small cell lung cancer
Camrelizumab
Platinum-containing dual-drug
Therapeutic effect
Lym⁃phocytes
